In South Korea’s biotech technology transfer market, the rise of “NewCo” companies is drawing attention. A NewCo is an independent entity established with investment from venture capital (VC) and other investors, centered around a specific scientific platform or pipeline.

Growth Research: "NewCos Are Rising in Korea’s Biotech Technology Transfer Market" View original image

Growth Research, an independent research firm, announced in a biotechnology industry report on July 6 that NewCos are emerging as a new core partner in the domestic biotech technology transfer market, complementing the big pharma-centric structure. The company analyzed that technology transfers through NewCos address the recurring structural limitations faced by Korean biotech firms, such as long development periods, massive clinical costs, and limited access to capital.


NewCos focus their capabilities on one or two assets, swiftly achieving clinical proof of concept (PoC) before recouping investment through an initial public offering (IPO) or mergers and acquisitions (M&A).


The primary strength of a NewCo is development speed. By concentrating resources on a specific asset and leveraging regulatory experts and contract research organization (CRO) networks from the outset, NewCos can conduct clinical design, manufacturing, and contracting in parallel, making them faster than traditional biotech companies. For example, obesity drug developer Metsera secured $290 million in April 2024 and initiated clinical dosing of its lead compound (MET-097i), advancing to Phase 2b clinical trials (VESPER-1) within just six months.


On average, it takes 10 to 15 years for a new drug to progress from discovery to approval, with development costs reaching several hundred billion won. For Korean biotech firms, the longer a clinical trial continues, the greater the R&D cost burden becomes; thus, technology transfer with NewCos can help accelerate development and ease funding pressures.



Han Yonghee, a researcher at Growth Research, explained, “Technology transfer with NewCos not only externalizes clinical development costs and increases speed through parallel development, but also reduces the ‘shelving risk’—where introduced assets fall in the internal priority list—setting it apart from big pharma-centric technology transfer.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing